undamentalytics Newsletter
Sign in

Ovid Therapeutics Inc. balance sheet

At the end of fiscal 2025, Ovid Therapeutics Inc. had total assets of $151m, total liabilities of $20.3m and shareholders' equity of $131m. It held $13.2m in cash against $0 of debt: net cash of $13.2m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents721884527261311
Total current assets751901311105674124
Total assets7619515514492151232
Accounts payable5724324
Deferred revenue (current)20—————
Total current liabilities221571111810
Total debt0000000
Total liabilities32152356242022
Shareholders' equity441801328868131210
Net debt (negative = net cash)−72−188−45−27−26−13−11
Shares outstanding66m70m70m71m71m130m185m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ABSI vs OVIDOVID vs RNACDARE vs OVIDMCRB vs OVID

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ovid Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ovid Therapeutics Inc.